The great hope of artificial intelligence in breast cancer is that it can distinguish harmless lesions from those likely to become malignant. By scanning millions of pixels, AI promises to help physicians find an answer for every patient far sooner, offering them freedom from anxiety or a better chance against a deadly disease.
But the Food and Drug Administration’s decision to grant clearances to these products without requiring them to publicly disclose how extensively their tools have been tested on people of color threatens to worsen already gaping disparities in outcomes within breast cancer, a disease which is 46% more likely to be fatal for Black women.
Oncologists said testing algorithms on diverse populations is essential because of variations in the way cancers manifest themselves among different groups. Black women, for instance, are more likely to develop aggressive triple-negative tumors, and are often diagnosed earlier in life at more advanced stages of disease.
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect